Printer Friendly

CYTOCARE ANNOUNCES LITIGATION VICTORY

 CYTOCARE ANNOUNCES LITIGATION VICTORY
 IRVINE, Calif., May 8 /PRNewswire/ -- The following is being issued


by Cytocare Inc.:
 Cytocare Inc. (NASDAQ: CYTI) announced today that Judge Stotler of the Central District, Santa Ana, granted summary judgment on all counts in favor of Cytocare and against plaintiffs in the class action lawsuit (Kaplan v. Rose) filed by plaintiffs in October of 1989.
 Cytocare's successful defense was headed by litigator Robert Currie of the Orange County office of Latham & Watkins. Latham attorneys Glenda Sanders, Chris Carlton and other attorneys, paralegals and staff were praised by the company for their efforts in achieving this victory. The class action plaintiffs were represented by Milberg Weiss Bershad Specthrie & Lerach.
 The summary judgment order was granted in favor of all defendants including Cytocare (successor to Medstone International Inc.), Weeden & Co. Inc. (the lead underwriter in the company's initial public offering in June 1988), and individual officers and directors. The suit was originally filed in October of 1989, during the company's effort to get FDA approval to extend the use of its lithotripter to include the treatment of gallstones. The company had received approval for the treatment of kidney stones in April 1988. FDA panel rejection of gallstone lithotripsy and the effect of the class action litigation contributed to a drop in the company's stock price.
 Cytocare observed that these lawsuits damage shareholder value by fostering extreme economic uncertainty which often results in pressure to capitulate to unreasonable settlement demands.
 Cytocare is developing a family of diagnostic and therapeutic pharmaceuticals and devices for prostate disease. Medstone International Inc., its manufacturing subsidiary, serves urology with lithotripsy products and procedures.
 -0- 5/8/92
 /CONTACT: Jeannine Cormane of Cytocare, 714-587-0500/
 (CYTI) CO: Cytocare Inc. ST: California IN: MTC SU:


CH -- LA012 -- 7978 05/08/92 09:25 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 8, 1992
Words:298
Previous Article:MYSTIC LAKE CASINO TOPIC OF PRESS CONFERENCE
Next Article:TOTAL PETROLEUM (NORTH AMERICA) HOLDS ANNUAL MEETING
Topics:


Related Articles
CYTOCARE BUYS RIGHTS TO PROSTATE CANCER ANTIBODIES
CYTOCARE, INC. REPORTS YEAR-END RESULTS
CYTOCARE REPORTS FIRST QUARTER RESULTS
CYTOCARE INC. ELECTS NEW DIRECTOR
CYTOCARE FILES 510(k) SUBMISSION FOR LASER CATHETER FOR LASER SURGERY OF UROLOGICAL TISSUES
Primus Innovations and Health Robotics Launch Strategic Partnership to Accelerate Transformation in Chemotherapy Compounding.
Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc.
ICU Medical Inc. and Health Robotics Announce Compatibility of CytoCare(TM) Robot and CLAVE(R) Needle-Free Connector to Enable Safer Hazardous Drug...
ICU Medical Inc. and Health Robotics Announce Compatibility of CytoCare(TM) Robot and CLAVE(R) Needle-Free Connector to Enable Safer Hazardous Drug...
Health Robotics Continues Global Expansion Into Oceania With Device Technologies Australia's Strategic Partnership.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters